XNASMIRM
Market cap1.98bUSD
Jan 10, Last price
41.32USD
1D
-1.62%
1Q
3.02%
IPO
206.07%
Name
Mirum Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
10.64
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.20%
Rev. gr., 5y
%
Revenues
186m
+141.85%
Net income
-163m
L+20.45%
CFO
-71m
L-40.95%
Earnings
Feb 26, 2025
Profile
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 186,374 141.85% | 77,062 302.66% | ||||
Cost of revenue | 295,528 | 208,282 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (109,154) | (131,220) | ||||
NOPBT Margin | ||||||
Operating Taxes | 991 | (6,406) | ||||
Tax Rate | ||||||
NOPAT | (110,145) | (124,814) | ||||
Net income | (163,415) 20.45% | (135,665) 61.53% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 216,684 | 114,639 | ||||
BB yield | -17.95% | -17.37% | ||||
| Debt | ||||||
Debt current | 2,208 | 931 | ||||
Long-term debt | 308,759 | 3,445 | ||||
Deferred revenue | 140,351 | |||||
Other long-term liabilities | 3,849 | 144,883 | ||||
Net debt | 24,641 | (347,343) | ||||
| Cash flow | ||||||
Cash from operating activities | (70,944) | (120,136) | ||||
CAPEX | (109) | (278) | ||||
Cash from investing activities | (107,200) | 7,700 | ||||
Cash from financing activities | 336,600 | 109,087 | ||||
FCF | (126,149) | (124,609) | ||||
| Balance | ||||||
Cash | 286,326 | 251,719 | ||||
Long term investments | 100,000 | |||||
Excess cash | 277,007 | 347,866 | ||||
Stockholders' equity | (554,590) | (393,037) | ||||
Invested Capital | 1,116,355 | 287,635 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 40,885 | 33,839 | ||||
Price | 29.52 51.38% | 19.50 22.26% | ||||
Market cap | 1,206,929 82.91% | 659,862 36.44% | ||||
EV | 1,231,570 | 312,519 | ||||
EBITDA | (98,325) | (127,539) | ||||
EV/EBITDA | ||||||
Interest | 15,105 | 15,979 | ||||
Interest/NOPBT | ||||||